(Q43583142)

English

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

scientific article published in February 2001

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Koen van Besien

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Richard E Champlin

11

object named as

Champlin R

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

7

object named as

Giralt S

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Rodriguez A

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tomany S

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Younes A

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Donato M

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sarris A

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mehra R

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Andersson B

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Gajewski J

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Cabanillas F

12

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

1 February 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

397-404

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

21 January 2018

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Ice pops to prevent melphalan-induced stomatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of cell-mediated cytotoxicity by recombinant tumor necrosis factor (TNF alpha)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702793

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1702793

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43583142&oldid=2206140423"